The Medication(s) listed below have been approved by the Food & Drug Administration (FDA) as orphan products for treatment of this condition. There may be other products available
that are not considered orphan products.
Burosumab (Brand name: Crysvita)
- Manufactured by
Ultragenyx Pharmaceutical, Inc.
FDA-approved indication: April 2018 approved for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.
National Library of Medicine Drug Information Portal